Company

Immuneering Corporation

Headquarters: Cambridge, MA, United States

Employees: 68

CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.

NASDAQ: IMRX

Detailed Description

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Immuneering Corporation has the following listings and related stock indices.


Stock: NASDAQ: IMRX wb_incandescent

Details

Headquarters:

245 Main Street

Cambridge, MA 02142

United States

Phone: 617 500 8080